Home
Projects
Specifications
Tarceva - Small Molecule EGFR-Tyrosine Kinase Inhibitor for Cancer
Email Article
 
Print
Key Facts
Key Data:
Drug (brand/generic)
Tarceva (erlotinib)
Company/licensee
OSI Pharmaceuticals, Genetech, Roche
Therapy class
Anti-neoplastic agent
Product description
EGFR-tyrosine kinase inhibitor
Current indication
NSCLC
Market sector
Oncology
Development status
Approved in US and Europe
Return to Project
Home
|
New On This Site
|
Products & Services
|
Company A-Z
|
Industry Projects
|
White Papers
|
Jobs & Careers
|
Press Releases
|
Events & Exhibitions
|
Newsletter
|
Organisations
|
About Us
|
Contact Us
|
Advertise With Us
|
Home
New On This Site
Products & Services
Company A-Z
Industry Projects
White Papers
Jobs & Careers
Press Releases
Events & Exhibitions
Newsletter
Advertise With Us
About Us
Client Area
For every phase of your drug development
Search